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To the Editor: Iatrogenic 
Creutzfeldt-Jakob disease (iCJD) is 
an acquired form of prion disease 
that has been declining in incidence 
since the mid-1990s (1). Worldwide, 
at least 226 cases of iCJD, including 
29 US cases, have been associated 
with administration of contaminated 
human growth hormone (hGH) from 
cadavers. Reported incubation periods 
ranged from 5 to 42 years (mean 17 
years) (2). Commercially produced 
cadaveric hGH has been associated 
with only 1 previously reported case 
of iCJD: CJD developed in a 39-year-
old Austrian man ≈22 years after he 
received commercial cadaveric hGH 
(Crescormon, Kabivitrum, Stockholm, 
Sweden) during 1984–1985 (3). We 
report a second case of probable 
iCJD acquired through treatment with 
commercial cadaveric hGH.
The patient was born at 32 
weeks’ gestation with subsequent 
developmental delay, agenesis 
of the corpus callosum, and 
panhypopituitarism. He demonstrated 
clinical and laboratory signs of growth 
hormone deficiency but was denied 
treatment with hGH through the US 
government–supported National 
Hormone and Pituitary Program 
(NHPP) because he did not meet the 
height requirement. Treatment with 
commercial cadaveric hGH began 
when he was 5.8 years of age and 
continued for 23 months (1983–1985). 
He received 1.5 units intramuscularly 
3× per week and was primarily 
treated with Asellacrin (Ares-Serono, 
Geneva, Switzerland). In early 
1984, for an unspecified duration, he 
received Crescormon (Kabivitrum) 
because of an Asellacrin shortage. 
Treatment was halted in 1985 because 
of iCJD concerns and resumed 2 years 
later with recombinant hGH.
At age 33, 26.5 years (range 
25.5–28 years) after the midpoint of 
commercial cadaveric hGH treatment, 
dizziness and gait imbalance 
developed, causing a fall. The patient’s 
mental status also began declining, 
and he never returned to his baseline 
status. Six months after illness 
onset, he experienced hallucinations, 
weakness of lower extremities, and 
limb ataxia. Seven months after the 
fall, he entered a state of akinetic 
mutism; he died 9 months after 
symptom onset. A lumbar puncture, 
performed 8 months after illness onset, 
demonstrated 14-3-3 proteins and an 
elevated cerebrospinal fluid (CSF) 
tau level of 14,111 pg/mL (decision 
point 1,150 pg/mL) (4), although the 
specimen was contaminated with 
blood (39,375 erythrocytes/μL). 
Electroencephalogram demonstrated 
severe diffuse encephalopathy. Two 
brain magnetic resonance imaging 
studies performed 8 months after 
illness onset indicated probable CJD, 
given lack of prior metabolic and 
anoxic insults (Figure). The patient 
was discharged from a referral hospital 
with this diagnosis; no postmortem 
analysis was conducted.
On the basis of World Health 
Organization criteria, we conclude 
that this patient had probable iCJD 
as a result of hGH treatment (5). The 
patient’s condition was treated with 2 
different formulations of commercial 
cadaveric hGH, including one of the 
same brands in the same year as that 
of the first reported patient with iCJD 
associated with commercial cadaveric 
hGH (3). The patient’s incubation 
period (25.5–28 years) is well within 
expectations (1).
Despite an ongoing active 
surveillance program that identified 
≈3,500 of ≈4,500 post-1977 
cadaveric hGH recipients in the 
US NHPP, all 29 CJD infections in 
NHPP recipients occurred among 
the estimated  ≈2,700 pre-1977 
recipients (1,2). This significant 
reduction in iCJD was attributed to 
the 1977 introduction of a highly 
selective, column chromatography 
step in the hormone purification 
protocol that can markedly reduce 
prion infectivity (1,2). As shown by 
the many iCJD cases linked to hGH 
in France, the efficacy of column 
chromatography purification steps 
may vary (1). Commercially derived 
cadaveric hGH was produced in 
different laboratories from those 
that produced NHPP-distributed 
hGH, and sufficient details regarding 
sourcing and production methods of 
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the commercial products are lacking. 
Approximately 10,000 persons, 
mostly outside the United States, 
received commercial cadaveric 
hGH produced by Kabivitrum, and 
substantially fewer persons received 
product from Ares-Serono (A.F. 
Parlow, pers. comm.). Identification 
through passive surveillance of 2 
CJD cases among recipients of such 
hGH further supports a causal, rather 
than chance, association between 
commercial hormone and CJD. It also 
suggests a difference in iCJD risk 
between post-1977 NHPP-distributed 
hGH and commercial cadaveric hGH.
Limitations of this report 
include the lack of neuropathologic 
confirmation and insufficient 
information to strongly implicate a 
single commercial cadaveric hGH 
product as infection source. The report 
of another iCJD case-patient who 
received Crescormon during the same 
period provides some evidence that 
the product was the source of prion 
contamination. Although the patient 
may have had sporadic CJD, his young 
age at disease onset (33 years) makes 
this unlikely (6).
This report suggests that a 
potential risk for iCJD in persons who 
received commercial cadaveric hGH 
should be considered. Also, clinicians 
should not assume that all cadaveric 
hGH administered after 1977 
carries the same risk for infectivity. 
In addition, when CJD is being 
considered as a clinical diagnosis, 
a history of exposure to cadaveric 
hGH should always be sought, even 
when patients have normal or tall 
stature. Finally, we recommend that 
when a clinical diagnosis of CJD is 
suspected, but before the patient’s 
death, the local caregivers, with the 
family, should initiate arrangements 
for a postmortem examination 
to confirm diagnosis (e.g., www.
cjdsurveillance.com).
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Figure.	 Maps	 showing	 axial	 fluid	 attenuated	 inversion	 recovery	 (FLAIR),	 diffusion-weighted	 imaging	 (DWI),	 and	 apparent	 diffusion	
coefficient	(ADC)	at	the	level	of	the	basal	nuclei	(top	row)	and	dorsal	frontoparietal	cortex	(bottom	row)	of	the	brain	of	a	33.8-year-old	
man	with	agenesis	of	 the	corpus	callosum,	schizencephaly,	and	heterotopia.	Note	 the	symmetrical	DWI	signal	hyperintensities	 in	 the	
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West Nile Virus 
Infection in Belgian 
Traveler Returning 
from Greece
To the Editor: West Nile virus 
(WNV) is an arthropod-borne virus 
that is transmitted to humans by mos-
quitos, primarily of the genus Culex. 
Most human infections are asymp-
tomatic. Clinical symptoms occur in 
≈20% of case-patients and include 
fever, headache, and myalgia; <1% of 
WNV infections develop into severe 
neuroinvasive disease (1).
The virus was discovered in 1937 
in the West Nile district of Uganda. 
WNV is endemic to parts of Africa, 
Europe, Asia, and the Middle East, 
and since its introduction in New York 
in 1999, in North America. In Eurasia, 
human WNV infections were first re-
ported in Israel and France during the 
1950s–1960s, and the first major out-
break in Romania occurred in 1996 
(1). The disease emerged recently 
in Greece; a large outbreak in 2010 
caused neuroinvasive disease in 197 
patients, of whom 33 died (2). Since 
2010, occasional and local epidemics 
have been ongoing in Greece, Italy, 
Romania, Hungary, Spain, and the 
Balkans (3,4).
Clinical diagnosis may be diffi-
cult because WNV infections resemble 
other (arbo)viral diseases. Laboratory 
diagnosis relies primarily on serologic 
testing. Reverse transcription PCR (RT-
PCR) can be used to detect viral RNA 
during the acute phase of the disease, 
but its use is hampered by the patient’s 
low-level and transient viremia (1).
We here describe a confirmed 
case of WNV encephalitis imported 
by a traveler returning from Greece. 
A 73-year-old Belgian woman, who 
had a medical history of lymphoma, 
traveled to Kavala city (Macedonia, 
Greece). On August 14, 2012, she 
sought treatment at the Kavala Gen-
eral Hospital with a 6-day history of 
fever, headache, malaise, nausea, con-
fusion, decline of consciousness, and 
neck stiffness. Results of laboratory 
testing on admission demonstrated an 
increased leukocyte count (9,670/µL; 
80% neutrophils) and lactate dehy-
drogenase level (522 IU/L), a low C-
reactive protein level (0.7 mg/dL), and 
hyponatremia (131 mEq/L). Cerebro-
spinal fluid (CSF) testing showed 90 
cells/µL (79% lymphocytes) and glu-
cose and protein levels of 72 and 100.9 
mg/dL, respectively. Serum obtained 
on August 15 was sent to the national 
reference laboratory at Aristotle Uni-
versity (Thessaloniki, Greece), and 
IgM against WNV was detected by 
ELISA (WNV IgM Capture DxSelect 
and IgG DxSelect; Focus Diagnostics, 
Cypress, CA, USA). IgG was absent. 
On the second day of hospitalization, 
the patient exhibited seizures (speech 
arrest); she was given phenytoin (1/2 
amp 3×/day intravenously). On Au-
gust 18, the patient was transferred to 
a private hospital. Further treatment 
included intravenous fluid, antipyret-
ics, antimicrobial drugs, mannitol, 
and oxygen. On August 30, she was 
returned by plane to Belgium.
CSF obtained 26 days after symp-
tom onset and serum obtained 29 days 
after symptom onset were sent to the 
Institute of Tropical Medicine (An-
twerp, Belgium) because of its func-
tion as a national reference center for 
Belgium. IgM and IgG against WNV 
were detected in both samples by 
ELISA (Focus Diagnostics) (Table). 
Immunofluorescence assays on serum 
revealed IgM against WNV only and 
IgG against West Nile, dengue, yellow 
fever, and Japanese encephalitis virus-
es, with the strongest reaction against 
WNV (Flavivirus Mosaic 1; Euroim-
mun, Lübeck, Germany). Real-time 
RT-PCR (adapted from [5]) on the 
serum demonstrated a weak positive 
signal. Repeated RNA extraction and 
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Table.	Laboratory	results	confirming	WNV	infection	of	73-year-old	woman, Greece, 2012*† 
Sample Date RT-PCR	(Ct value) WNV	ELISA	IgM	(ratio) WNV	ELISA IgG	(ratio) Flavi	IFAT IgM Flavi	IFAT IgG 
Serum Aug	15 Positive	(45.47) Positive	(25) Negative ND ND 
CSF Sep	3 ND Positive	(5.16) Positive	(2.21) ND ND 
Serum Sep	6 Positive (42.87)‡ Positive	(4.76) Positive	(2.63) WNV	positive WNV	positive§ 
*WNV,	West	Nile	virus;	RT-PCR,	reverse	transcription	PCR;	Ct,	cycle	threshold;	Flavi,	flavivirus;	IFAT,	indirect	fluorescent	antibody	technique;	ND,	not	
done;	CSF,	cerebrospinal	fluid. 
†The ELISA is positive if ratio >1.1 for IgM and >1.5 for IgG. The cutoff value for IFAT is 1/10 for both IgG and IgM.  
‡Sequencing	revealed	a	116-bp	sequence	perfectly	matched to	the	WNV	amplicon	and	is	highly	suggestive	for	WNV	lineage	2	on	the	basis	of	the	
presence	of	2	specific	nucleotides.	 
§Strongest	signal	for	WNV,	weak	signal	for	other	flaviviruses	(Japanese	encephalitis	virus,	dengue	viruses	1–4,	yellow	fever	virus). 
 
